Developer docs
API playgroundTry for free, no card

Search company profiles

Igyxos

Full company profile

uuid0000i5v

Namestring
Igyxos
Legal namestring
Igyxos S.A.
Websiteurl
igyxos.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody (mAb) designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men and women. Founded in 2017 by Dr. Marie-Christine Maurel as a spin-out from ReproPharm, the company is headquartered at the INRAe Val de Loire research center in Nouzilly, France, and operates with 1–10 employees.

IGX12 operates through a novel conformational mechanism of action: the antibody binds to both FSH and the FSH receptor, facilitating receptor interaction and significantly improving FSH receptor activation. Preclinical evidence demonstrates enhanced ovarian stimulation (3x higher output in cynomolgus monkeys) and boosted spermatogenesis (approximately 6-fold increase in motile sperm count in hypogonadal mice models). The drug candidate has a long half-life (~43 days) supportive of monthly dosing, potentially reducing injection burden relative to current FSH therapies that require multiple injections per cycle. Igyxos completed Phase 1 Single Ascending Dose (32 healthy volunteers, March 2025) and Multiple Ascending Dose (14 healthy male volunteers, December 2025) trials with favorable safety profiles and is preparing Phase 2 trials in European fertility centers for 2026.

Igyxos is pre-revenue and monetizes through future commercialization of IGX12 via fertility clinics and healthcare providers globally. Current operations are funded by approximately EUR 27 million in cumulative capital — EUR 19 million in equity (EUR 7.5M Series A led by Bpifrance in 2019) and EUR 8 million in grants, loans and repayable advances, including a EUR 5.7 million France 2030 grant awarded in October 2025. The company executes CMC and clinical work through service partnerships with Merck Biodevelopment, Baccinex, Selexis, ERBC, and CRS Berlin. Key investors include Bpifrance, GO Capital, UI Investissement, and Sofimac Innovation.

Short descriptiontext

Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class monoclonal antibody that enhances FSH bioactivity to treat infertility in both men and women, with Phase 2 trials planned for 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNouzilly, France
HQ citystring
Nouzilly
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, fertility treatment development, reproductive health biopharmaceuticals, infertility therapeutics research, gonadotropin enhancing antibodies
Industry1 code
PRIMARYHLAKAJAC
Reproductive Endocrinology & Infertility (IVF/Fertility)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
Product category
Reproductive Health Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Igyxos is developing IGX12, a first-in-class monoclonal antibody therapeutic for infertility treatment. As a pre-revenue clinical-stage biotech, the company does not currently generate product revenue. Future revenue will come from commercialization of IGX12 for treatment of male and female infertility through fertility clinics and healthcare providers globally.

igyxos.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Igyxos is a clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody therapeutic designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men (oligozoospermia) and women (ovarian stimulation for IVF/assisted reproduction). The antibody binds to both FSH and the FSH receptor, inducing conformational changes that significantly improve receptor binding and FSH receptor activation. Igyxos is currently pre-revenue with Phase 1 trials completed in 2025 and Phase 2 trials planned at European fertility centers in 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 1 SAD study completed in 32 healthy volunteers (16 men, 16 women) with excellent safety profile and no serious adverse events
+4 more records
Product overview1 text field

Igyxos is a clinical-stage biotechnology company developing a single therapeutic product, IGX12, a first-in-class potentiating monoclonal antibody designed to enhance FSH (Follicle Stimulating Hormone) activity for the treatment of infertility in both men and women. The company's approach addresses a significant unmet medical need, as there are currently no approved treatments for male infertility despite it accounting for approximately 50% of infertility cases. IGX12 operates through a novel mechanism of action that boosts FSH bioactivity, potentially reducing the number of injections required and improving treatment outcomes compared to standard FSH therapy. The company is advancing IGX12 through Phase 1 clinical trials with Phase 2 trials planned for 2026.

Product and service1 record
1IGX12
CategoryInfertility Therapeutics
Description

IGX12 is a first-in-class humanized monoclonal antibody (mAb) therapeutic designed to enhance the potency and efficacy of Follicle Stimulating Hormone (FSH). It binds to FSH and facilitates its interaction with the FSH receptor, resulting in increased receptor activation and improved gametogenesis. IGX12 targets treatment of infertility in both men (oligozoospermia) and women (IVF/assisted reproduction). Currently in Phase 1 clinical development with Phase 2 trials planned for 2026.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-01
Description

CRS was selected by Igyxos for the performance of its Phase 1 clinical studies which were initiated in 2023 at CRS Berlin, a dedicated phase I clinical trials unit.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-01
Description

From 2022, ERBC has been performing the toxicological studies in animals to support IGX12 entry into clinics.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

In 2021, Baccinex and Igyxos entered into a service agreement under which Baccinex produces IGX12 Drug Product for clinical studies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-09-02
Description

In 2020, Selexis and Igyxos entered into a service agreement to utilize Selexis' proprietary SUREtechnology Platform to rapidly develop the cell line to advance IGX12 into human trials. Selexis, a JSR Life Sciences company and global leader in cell line development, provides high-expressing, stable, production-ready research cell banks.

5Merck Biodevelopment (EMD Millipore)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

In 2020, Merck and Igyxos entered into a service agreement to produce IGX12 to support pre-clinical and phase I/II clinical studies. Merck provides manufacturing services for the monoclonal antibody.

igyxos.com
6Centre Val de Loire
Strategic tierMinorTypeOthers
Description

Regional government support organization providing funding and support to companies in the Centre-Val de Loire region of France.

igyxos.com
Strategic tierMinorTypeOthers
Description

Regional innovation and business development organization supporting companies in the Pays de la Loire region.

Strategic tierMinorTypeOthers
Description

French national research institute. Igyxos is based at the INRAe Val de Loire site in Nouzilly, reflecting historical ties to reproductive health research conducted at INRA.

Strategic tierMinorTypeOthers
Description

French National Institute of Health and Medical Research, a public research institute supporting biomedical research in France.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Private global biopharma specializing in reproductive medicine and women's health (e.g., Menopur, Bravelle). Directly comparable as the established leader in fertility therapeutics that any novel FSH-potentiating mAb would compete against.

TypeBroad incumbent
Description

Public women's health spinoff from Merck with a major fertility franchise (e.g., Follistim, Ganirelix). Directly comparable as a large reproductive-health incumbent whose commercial footprint and lifecycle management strategy IGX12 would need to challenge.

3Merck KGaA (Healthcare)
TypeBroad incumbent
Description

Markets Gonal-f (recombinant FSH), the dominant gonadotropin in IVF. Directly comparable as the standard-of-care FSH therapy that IGX12 is designed to potentiate, and a likely commercial partner or competitive threat.

TypeDirect peer
Description

Clinical-stage Swiss biotech developing women's health therapeutics for reproductive indications (Yselty for uterine fibroids/endometriosis). Directly comparable as a small-cap clinical-stage women's/reproductive health biotech in Europe, with similar partnership dynamics.

TypeBroad incumbent
Description

Hungarian-headquartered pharma with a meaningful women's health/fertility portfolio. Comparable as an established reproductive-medicine player that could pursue or partner a novel FSH-potentiating mechanism.

TypeDirect peer
Description

London-listed clinical-stage biotech focused on rare diseases including women's health and reproductive indications. Comparable as a small European clinical-stage biotech with a similar partnership-and-pivot operating model.

TypeBroad incumbent
Description

Private global women's health company with a fertility and reproductive endocrinology portfolio. Comparable as a focused reproductive-health commercial-stage player that could be a regional licensing/distribution partner for IGX12.

TypeEmerging player
Description

European contract drug discovery and development company with active programs in reproductive health. Comparable as an enabling partner in the European biotech ecosystem, though positioned more as a service provider than a fertility asset developer.

9PregLem
TypeOthers
Description

Swiss women's health biotech (now Gedeon Richter subsidiary) that developed Esmya (ulipristal acetate) for uterine fibroids, led by Dr. Elke Bestel (now Igyxos CMO). Comparable thematically as a women's reproductive-health biotech whose leadership now sits on Igyxos.

TypeOthers
Description

French clinical-stage cell and gene therapy biotech. Comparable as a French clinical-stage biotech of similar vintage with comparable operational benchmarks, though unrelated in therapeutic area; Igyxos COO Thierry Ziegler previously led cell therapy production there.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Igyxos

Reproductive Health Biopharmaceuticalsigyxos.com

Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class monoclonal antibody that enhances FSH bioactivity to treat infertility in both men and women, with Phase 2 trials planned for 2026.

What Igyxos does

Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody (mAb) designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men and women. Founded in 2017 by Dr. Marie-Christine Maurel as a spin-out from ReproPharm, the company is headquartered at the INRAe Val de Loire research center in Nouzilly, France, and operates with 1–10 employees.

IGX12 operates through a novel conformational mechanism of action: the antibody binds to both FSH and the FSH receptor, facilitating receptor interaction and significantly improving FSH receptor activation. Preclinical evidence demonstrates enhanced ovarian stimulation (3x higher output in cynomolgus monkeys) and boosted spermatogenesis (approximately 6-fold increase in motile sperm count in hypogonadal mice models). The drug candidate has a long half-life (~43 days) supportive of monthly dosing, potentially reducing injection burden relative to current FSH therapies that require multiple injections per cycle. Igyxos completed Phase 1 Single Ascending Dose (32 healthy volunteers, March 2025) and Multiple Ascending Dose (14 healthy male volunteers, December 2025) trials with favorable safety profiles and is preparing Phase 2 trials in European fertility centers for 2026.

Igyxos is pre-revenue and monetizes through future commercialization of IGX12 via fertility clinics and healthcare providers globally. Current operations are funded by approximately EUR 27 million in cumulative capital — EUR 19 million in equity (EUR 7.5M Series A led by Bpifrance in 2019) and EUR 8 million in grants, loans and repayable advances, including a EUR 5.7 million France 2030 grant awarded in October 2025. The company executes CMC and clinical work through service partnerships with Merck Biodevelopment, Baccinex, Selexis, ERBC, and CRS Berlin. Key investors include Bpifrance, GO Capital, UI Investissement, and Sofimac Innovation.

Igyxos firmographics

Firmographics
Name
Igyxos
Legal name
Igyxos S.A.
Website
https://igyxos.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class monoclonal antibody that enhances FSH bioactivity to treat infertility in both men and women, with Phase 2 trials planned for 2026.
Ownership category
akta.pro rank

Igyxos industry classification

Industry
Product category
Reproductive Health Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
akta.pro industry
PRIMARYHLAKAJAC
Reproductive Endocrinology & Infertility (IVF/Fertility)

Keywords

  • Monoclonal antibody therapeutics
  • Fertility treatment development
  • Reproductive health biopharmaceuticals
  • Infertility therapeutics research
  • Gonadotropin enhancing antibodies

Where Igyxos is headquartered

Location

Headquarters

HQ city
Nouzilly
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Igyxos business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Igyxos is developing IGX12, a first-in-class monoclonal antibody therapeutic for infertility treatment. As a pre-revenue clinical-stage biotech, the company does not currently generate product revenue. Future revenue will come from commercialization of IGX12 for treatment of male and female infertility through fertility clinics and healthcare providers globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Igyxos product offering

Product offering

Core offering

Igyxos is a clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody therapeutic designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men (oligozoospermia) and women (ovarian stimulation for IVF/assisted reproduction). The antibody binds to both FSH and the FSH receptor, inducing conformational changes that significantly improve receptor binding and FSH receptor activation. Igyxos is currently pre-revenue with Phase 1 trials completed in 2025 and Phase 2 trials planned at European fertility centers in 2026.

Product overview

Igyxos is a clinical-stage biotechnology company developing a single therapeutic product, IGX12, a first-in-class potentiating monoclonal antibody designed to enhance FSH (Follicle Stimulating Hormone) activity for the treatment of infertility in both men and women. The company's approach addresses a significant unmet medical need, as there are currently no approved treatments for male infertility despite it accounting for approximately 50% of infertility cases. IGX12 operates through a novel mechanism of action that boosts FSH bioactivity, potentially reducing the number of injections required and improving treatment outcomes compared to standard FSH therapy. The company is advancing IGX12 through Phase 1 clinical trials with Phase 2 trials planned for 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • IGX12 IGX12 is a first-in-class humanized monoclonal antibody (mAb) therapeutic designed to enhance the potency and efficacy of Follicle Stimulating Hormone (FSH). It binds to FSH and facilitates its interaction with the FSH receptor, resulting in increased receptor activation and improved gametogenesis. IGX12 targets treatment of infertility in both men (oligozoospermia) and women (IVF/assisted reproduction). Currently in Phase 1 clinical development with Phase 2 trials planned for 2026.

Quantifiable outcome

  • Phase 1 SAD study completed in 32 healthy volunteers (16 men, 16 women) with excellent safety profile and no serious adverse events
  • +4 more outcomes

Companies that use Igyxos

Customer profile

Segments2 records

Ideal customer profiles2 records

Igyxos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Igyxos partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • CRS (Berlin)coreTechnology or Integration · 1 January 2023CRS was selected by Igyxos for the performance of its Phase 1 clinical studies which were initiated in 2023 at CRS Berlin, a dedicated phase I clinical trials unit.
  • ERBCcoreTechnology or Integration · 1 January 2022From 2022, ERBC has been performing the toxicological studies in animals to support IGX12 entry into clinics.
  • BaccinexcoreTechnology or Integration · 1 January 2021In 2021, Baccinex and Igyxos entered into a service agreement under which Baccinex produces IGX12 Drug Product for clinical studies.
  • SelexiscoreTechnology or Integration · 2 September 2020In 2020, Selexis and Igyxos entered into a service agreement to utilize Selexis' proprietary SUREtechnology Platform to rapidly develop the cell line to advance IGX12 into human trials. Selexis, a JSR Life Sciences company and global leader in cell line development, provides high-expressing, stable, production-ready research cell banks.
  • Merck Biodevelopment (EMD Millipore)coreTechnology or Integration · 1 January 2020In 2020, Merck and Igyxos entered into a service agreement to produce IGX12 to support pre-clinical and phase I/II clinical studies. Merck provides manufacturing services for the monoclonal antibody.
  • Centre Val de LoireminorOthersRegional government support organization providing funding and support to companies in the Centre-Val de Loire region of France.
  • AtlanpoleminorOthersRegional innovation and business development organization supporting companies in the Pays de la Loire region.
  • INRAe (National Institute for Agricultural Research)minorOthersFrench national research institute. Igyxos is based at the INRAe Val de Loire site in Nouzilly, reflecting historical ties to reproductive health research conducted at INRA.
  • INSERMminorOthersFrench National Institute of Health and Medical Research, a public research institute supporting biomedical research in France.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Igyxos competitors and assessment

Company assessment

Broad incumbents

  • Ferring Pharmaceuticals: Private global biopharma specializing in reproductive medicine and women's health (e.g., Menopur, Bravelle). Directly comparable as the established leader in fertility therapeutics that any novel FSH-potentiating mAb would compete against.
  • Organon: Public women's health spinoff from Merck with a major fertility franchise (e.g., Follistim, Ganirelix). Directly comparable as a large reproductive-health incumbent whose commercial footprint and lifecycle management strategy IGX12 would need to challenge.
  • Merck KGaA (Healthcare): Markets Gonal-f (recombinant FSH), the dominant gonadotropin in IVF. Directly comparable as the standard-of-care FSH therapy that IGX12 is designed to potentiate, and a likely commercial partner or competitive threat.
  • Gedeon Richter: Hungarian-headquartered pharma with a meaningful women's health/fertility portfolio. Comparable as an established reproductive-medicine player that could pursue or partner a novel FSH-potentiating mechanism.
  • Theramex: Private global women's health company with a fertility and reproductive endocrinology portfolio. Comparable as a focused reproductive-health commercial-stage player that could be a regional licensing/distribution partner for IGX12.

Direct peers

  • ObsEva: Clinical-stage Swiss biotech developing women's health therapeutics for reproductive indications (Yselty for uterine fibroids/endometriosis). Directly comparable as a small-cap clinical-stage women's/reproductive health biotech in Europe, with similar partnership dynamics.
  • Mereo BioPharma: London-listed clinical-stage biotech focused on rare diseases including women's health and reproductive indications. Comparable as a small European clinical-stage biotech with a similar partnership-and-pivot operating model.

Emerging players

  • Evotec: European contract drug discovery and development company with active programs in reproductive health. Comparable as an enabling partner in the European biotech ecosystem, though positioned more as a service provider than a fertility asset developer.

Others

  • PregLem: Swiss women's health biotech (now Gedeon Richter subsidiary) that developed Esmya (ulipristal acetate) for uterine fibroids, led by Dr. Elke Bestel (now Igyxos CMO). Comparable thematically as a women's reproductive-health biotech whose leadership now sits on Igyxos.
  • Cellectis: French clinical-stage cell and gene therapy biotech. Comparable as a French clinical-stage biotech of similar vintage with comparable operational benchmarks, though unrelated in therapeutic area; Igyxos COO Thierry Ziegler previously led cell therapy production there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Igyxos social profiles

Digital presence

Igyxos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Igyxos leadership team

Management profile

Number of profiles

Profiles5 records

Igyxos funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Igyxos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Igyxos

What does Igyxos do?

Igyxos is a clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody therapeutic designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men (oligozoospermia) and women (ovarian stimulation for IVF/assisted reproduction). The antibody binds to both FSH and the FSH receptor, inducing conformational changes that significantly improve receptor binding and FSH receptor activation. Igyxos is currently pre-revenue with Phase 1 trials completed in 2025 and Phase 2 trials planned at European fertility centers in 2026.

Is Igyxos a public or private company?

Igyxos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Igyxos founded?

Igyxos was founded in 2017. It employs 11 to 50 people.

Where is Igyxos based?

Igyxos is headquartered in Nouzilly, France, in the Europe region.

How does Igyxos make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Igyxos's main competitors?

Broad incumbents on record are Ferring Pharmaceuticals, Organon, Merck KGaA (Healthcare), Gedeon Richter and Theramex. Direct peers are ObsEva and Mereo BioPharma. Evotec is listed as an emerging player. Others are PregLem and Cellectis.

Does Igyxos have an API?

No public API is recorded for Igyxos.

What industry is Igyxos in?

Igyxos's product category is Reproductive Health Biopharmaceuticals. Its primary akta.pro industry code is HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 325412.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyCan biotech finally fix infertility?Biotech firms are developing drugs to improve IVF outcomes by targeting upstream biology, such as endometrial receptivity and male infertility. IVF success rates vary, with implantation failure affecting 10% of couples, and no approved treatment exists for male factor infertility. Companies like Igyxos and Oxolife are advancing therapies, but clinical endpoints remain unforgiving.Labiotech.euThe future of male infertility treatmentSeveral biotech companies are developing new treatments for male infertility, a field that has been largely neglected despite affecting roughly half of fertility cases in heterosexual couples, with Igyxos reporting successful Phase 1 trials for its drug IGX12 and planning Phase 2 trials in Europe for 2026. The article profiles multiple emerging therapies including Paterna Biosciences' in vitro spermatogenesis technology, Repronovo's leflutrozole in Phase 2 trials, and XY Therapeutics' single-injection treatment, all targeting the treatment gap where women currently bear the physical and financial burden of IVF procedures. France has announced plans to combat infertility through awareness campaigns and improved egg freezing access, though these measures do not address male infertility, which experts say lags approximately 30 years behind female-focused treatments.GlobeNewswireIgyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female InfertilityIgyxos Biotherapeutics announced successful completion of its Phase 1 Multiple Ascending Dose clinical trial of IGX12, a first-in-class monoclonal antibody for treating infertility in both men and women. The randomized, placebo-controlled trial in 14 healthy male volunteers at two dose levels demonstrated an excellent safety profile with no serious adverse events reported, and the pharmacokinetic profile supports monthly dosing. The company plans to initiate Phase 2 trials at leading European fertility centers in 2026.PharmiWeb.comIgyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female InfertilityIgyxos Biotherapeutics announced successful completion of its Phase 1 Multiple Ascending Dose trial of IGX12 in 14 healthy male volunteers, demonstrating an excellent safety profile at both doses with no serious adverse events reported. The pharmacokinetic profile showed gradual absorption and slow elimination half-life characteristics supportive of monthly dosing for fertility treatment. The company is planning Phase 2 trials at leading fertility centers in Europe in 2026.Labiotech.euRethinking infertility treatment: Treating couples, not just womenIgyxos Biotherapeutics, a clinical-stage biotech company, is developing IGX12, a first-in-class humanized monoclonal antibody that enhances follicle-stimulating hormone (FSH) bioactivity to treat infertility in both men and women, with the goal of addressing male infertility which accounts for approximately 50% of infertility cases but has no approved therapies. The therapy has completed preclinical studies and a Phase 1 single ascending dose study demonstrating an excellent safety profile, with Phase 1 multiple ascending dose results in male volunteers expected by early December. The article argues that current IVF-based treatment paradigms, which cost $20,000-$25,000 per cycle in the US with only 25-30% success rates, have not innovated in decades and place the full physical burden on women.GlobeNewswireIgyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of InfertilityIgyxos Biotherapeutics received a EUR 5.7 million grant from the French government to fund Phase 2 clinical trials of its lead asset IGX12, a monoclonal antibody for infertility. The funding will support trials in France and Europe, with Phase 1 results expected in Q4 2025.YahooIgyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of InfertilityIgyxos Biotherapeutics received a EUR 5.7 million grant from the French government to fund Phase 2 clinical trials of its lead asset IGX12, a monoclonal antibody for infertility. The non-dilutive funding will support trials in France and Europe, with Phase 1 results expected in Q4 2025.BioSpaceIgyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of InfertilityIgyxos Biotherapeutics has secured a EUR 5.7 million non-dilutive grant from the French government under the France 2030 programme, administered by Bpifrance, to fund Phase 2 clinical trials of IGX12, a first-in-class monoclonal antibody designed to enhance FSH efficacy for treating infertility in both men and women. Phase 1 results demonstrated good safety and tolerability in both sexes, with the company expecting to report further Phase 1 data in Q4 2025. The funding accelerates development of what could become the first approved treatment for male infertility, which accounts for nearly half of all infertility cases.FinSMEsIgyxos raises €7.5M in Series A FundingIgyxos, a French biotech company, raised €7.5M in Series A funding from Bpifrance, Go Capital, and Sofimac Innovation. The funds will finance development of its monoclonal antibody drug candidate for infertility until proof of concept in human clinical trials.